0001193125-26-213269
SEC filingBoundless Bio reported Q1 2026 financial results with net loss of $13.6 million, reduced R&D and G&A expenses, and $92.8 million cash runway through second half of 2028 amid ongoing KOMODO-1 trial enrollment.
Boundless Bio's Q1 2026 results reflect disciplined cost management in a clinical-stage biotech, with R&D expenses declining 20% year-over-year to $9.7 million, likely due to optimized trial preparations for KOMODO-1, the first-in-human study of BBI-940 targeting ecDNA+ cancers via kinesin degradation. G&A expenses also fell 9% to $4.7 million, contributing to a narrower net loss of $13.6 million versus $15.8 million in Q1 2025, alongside higher interest income of $0.9 million. CEO Zachary Hornby highlighted trial progress and preclinical validation from AACR 2026, where BBI-940 demonstrated ecDNA mis-segregation, reduced viability in ecDNA+ cells, and tumor regressions in breast cancer models, including ecDNA+/FGFR1+ ER+ with fulvestrant. Cash of $92.8 million as of March 31 provides runway through H2 2028, covering anticipated proof-of-concept data from KOMODO-1 in ER+/HER2- breast cancer post-CDK4/6 and TNBC-LAR patients. This positions the company to advance its ecDNA-directed therapy without near-term dilution risk, though forward-looking statements note risks like trial delays and funding needs.